FINWIRES · TerminalLIVE
FINWIRES

Purpose Investments Announces Increased Staking for Purpose Solana ETF

By

-- Purpose Investments is increasing the proportion of Solana staked within Purpose Solana ETF (TSX: SOLL, SOLL.B, SOLL.U), effective on or about April 28, the company said after markets closed on Tuesday.

The move, from 50% staked to up to 100% staked, is designed to increase the net staking yield earned by the Fund while continuing to maintain reasonable liquidity management practices, said the company.

Staking within the Fund is powered by Purpose's proprietary in-house Solana validator infrastructure, operated through Purpose Unlimited Inc, said the company and added that this approach reduces third-party staking fees and, is expected to result in higher net staking rewards for the Fund and in turn Unitholders.

"Increasing the staking level within SOLL is a natural next step as our operational infrastructure proves out," said Paul Pincente, VP of Digital Assets. "Our liquidity-first approach means investor access to their capital remains the priority - staking is optimized around that approach, not at its expense."

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS